About Hummingbird Bioscience
Hummingbird Bioscience is a company based in Singapore (Singapore) founded in 2015 by Lan Zhang and Jerome Boyd-Kirkup. Hummingbird Bioscience has raised $150 million across 6 funding rounds from investors including SK, Frazier Healthcare Partners and Novo Holdings. Hummingbird Bioscience offers products and services including ADC Platform and Antibody Platform. Hummingbird Bioscience operates in a competitive market with competitors including ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
- Headquarter Singapore, Singapore
- Founders Lan Zhang, Jerome Boyd-Kirkup
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$150 M (USD)
in 6 rounds
-
Latest Funding Round
$125 M (USD), Series C
May 17, 2021
-
Investors
SK
& 22 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hummingbird Bioscience
Hummingbird Bioscience offers a comprehensive portfolio of products and services, including ADC Platform and Antibody Platform.
Platform for developing antibody-drug conjugates targeting cancer.
Technology for engineering precision antibody therapeutics.
Funding Insights of Hummingbird Bioscience
Hummingbird Bioscience has successfully raised a total of $150M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hummingbird Bioscience
Hummingbird Bioscience has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include SK, Frazier Healthcare Partners and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Locked | Locked | Locked |
Investor details for Hummingbird Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hummingbird Bioscience
Investment portfolio details for Hummingbird Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hummingbird Bioscience
Detailed financials for Hummingbird Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hummingbird Bioscience Comparisons
Peer comparison for Hummingbird Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hummingbird Bioscience
Hummingbird Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
Detailed competitors of Hummingbird Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hummingbird Bioscience
Complete news archive for Hummingbird Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hummingbird Bioscience
Hummingbird Bioscience was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Hummingbird Bioscience is headquartered in Singapore, Singapore.
Hummingbird Bioscience is a funded company, having raised a total of $150M across 6 funding rounds to date.
The company was founded in 2015 in Singapore and operates in the biotechnology sector. Antibodies for cancer therapy are developed through systems immunology and computational structural biology. Platform technology is utilized for the design of therapeutic antibodies. The pipeline includes HMBD-001, a monoclonal antibody, and HMBD-002, an anti-VISTA monoclonal antibody targeted at cancer treatment.
Hummingbird Bioscience's top competitors include Alector, Lyell Immunopharma and Alpine Immune Sciences.
Hummingbird Bioscience offers ADC Platform and Antibody Platform.
Hummingbird Bioscience has 23 investors. Key investors include SK, Frazier Healthcare Partners, Novo Holdings, Octagon Capital Advisors, and EDBI.